Skip to main content
All Posts By

Clinic Hours

Rice grain calcification in cysticercosis

History: A 56 year old female presented to ED with 1 episode of GTC seizure. Neurological examination was normal except for postictal confusion. NCCT brain showed multiple calcified granuloma, some showing perilesional oedema in the frontal, parietal & occipital lobes. Routine CXR showed typical rice-grain-shaped calcification in the chest wall muscles. Xray thigh and forearm were ordered which showed similar lesions. What’s the diagnosis?

Answer: Rice grain calcification is characteristic of infection with Taenia solium (cysticercosis); when the inflammatory response of the host kills the larval cysts (cysticerci), they undergo granulomatous change and become calcified. Demonstration of rice-grain clacification on plain radiograph is a minor diagnostic criterion for neurocysticercosis (NCC). Their presence support NCC as the cause of ring-enhancing lesions in brain imaging.

Clinical Rounds by ClinicHours

FDA expands Atogepant approval for chronic migraine

Atogepant is the first and only, oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine. Dose: 60 mg dose 1 OD in chronic migraine. 30 mg and 60 mg for prevention of episodic migraine.

Clinical Inshorts by ClinicHours

Global Strategy for Diagnosis, Management & Prevention of COPD 2023 Updates

The 2023 GOLD report contains numerous updates:

Chapter 1
► A new definition of COPD has been proposed (Page 5)
► A section on Chronic Bronchitis has been added (Page 13)
► A table has been added with Proposed Taxonomy (Etiotypes) for COPD (Table 1.1)

Chapter 2
► Additional information on screening for COPD and case-finding has been included (Page 36)
► Information on Imaging and Computed Tomography (CT) has been included (Page 43)
► A table with information on the Use of CT in Stable COPD has been added (Table 2.8)

Chapter 3
► Vaccination Recommendations for people with COPD have been updated in line with current guidance from the CDC (Page 54)
► Further information on therapeutic interventions to reduce COPD mortality has been added (Page 67)
► A table has been added with information on the Evidence Supporting a Reduction in Mortality with Pharmacotherapy and Non-pharmacotherapy in COPD Patients (Table 3.6)
► Issues Related to Inhaled Delivery have been addressed (Page 69)
► Information on the topic of Adherence to Inhaled COPD Medications has been included (Page 71)
► A section on Tele-rehabilitation has been added (Page 76) Page 2 of 16
► The section on Interventional & Surgical Therapies for COPD has been expanded (Page 82)
► A figure has been added giving an Overview of Current and Proposed Surgical and Bronchoscopic Interventions for People with COPD (Figure 3.2)

Chapter 4
► A section on the choice of inhaler device has been added (Page 112)
► A table has been added with information on Basic Principles for Appropriate Inhalation Device Choice (Table 4.5)
► The ABCD Assessment Tool has been revised to the ABE Assessment Tool to recognize the clinical relevance of exacerbations, independent of the level of symptoms (Page 115)
► The information and figures outlining Initial Pharmacological Treatment and Follow-up Pharmacological Treatment have been updated. In particular, the positioning of LABA+LAMA and of LABA+ICS has been changed (Page 115)

Chapter 5
► The topic of management of exacerbations has been expanded to include details of possible alternative causes
of symptoms
► A new definition of COPD Exacerbation and a new set of parameters to assess exacerbation severity at the point of care has been included (Page 134)
► A new paragraph and a new figure on the Classification of the Severity of COPD Exacerbations have been added (Figure 5.1)
► A new table on Diagnosis and Assessment has been added (Table 5.3)

Chapter 6
► The chapter on COPD and Co-morbidities has been updated with the latest evidence.

Chapter 7
► The chapter on COVID-19 and COPD has been updated with new references and the latest evidence.

Download 2023 GOLD guide
Clinical Inshorts by ClinicHours

FDA approves Dabrafenib with Trametinib for pediatric gliomas

The US FDA has approved dabrafenib with trametinib for children aged 1 year or older who need systemic treatment for low-grade gliomas that have a BRAF V600E mutation. Dabrafenib/trametinib is the first systemic therapy approved for frontline treatment of low-grade, BRAF-mutated pediatric gliomas, the FDA said. Dabrafenib was given orally twice daily, and trametinib was given orally once daily. Children in the chemotherapy arm received a 10-week induction course followed by eight 6-week maintenance cycles.

Adverse effects: pyrexia (66%), rash (54%), headache (40%), vomiting (38%), musculoskeletal pain (36%), fatigue (31%), dry skin (31%), diarrhea (30%), nausea (26%), epistaxis and other bleeding events (25%), abdominal pain (24%), and dermatitis acneiform (23%). The more common grade 3 or 4 laboratory abnormalities were decreased neutrophil count (20%) and increases in alanine aminotransferase (3.1%) and aspartate aminotransferase levels (3.1%).

Clinical Inshorts by ClinicHours

Duchenne muscular dystrophy case

History: A 14 year-old boy presented with progressive proximal weakness of the lower limbs starting at 4 years of age followed by involvement of the upper limbs. He is the product of a consanguineous marriage. Clinically, he had flaccid quadriparesis with wasting and contractures without any sensory or neurological involvement. His weakness worsened leading to an inability to walk without support by the age of 8 and total wheelchair dependence by the age of 11. He was frequently admitted to hospital with chest infections. The patient’s creatine kinase was 2600 IU/L (normal 50–150 IU/L) and muscle biopsy from left quadriceps showed rounded small muscle fibres with evidence of degeneration and an absence of dystrophin protein. What’s the diagnosis?

Answer: Duchenne muscular dystrophy is a X-linked recessive genetic disorder.

Cause: Gene mutation of dystrophin protein.

Signs and symptoms: Muscle weakness, scoliosis, Respiratory Infections, Gowers’s sign.

Diagnosis: Creatine kinase (CPK-MM), DNA test, Muscle biopsy, Prenatal tests.

Treatment:

  • Corticosteroids such as prednisolone and deflazacort lead to short-term improvements in muscle strength and function up to 2 years.
  • The medication eteplirsen, a Morpholino antisense oligo for the treatment of mutations amenable to dystrophin exon 51 skipping.
  • The medication ataluren (Translarna) is approved for use in the European Union.
  • The antisense oligonucleotide golodirsen (Vyondys 53) was approved for medical use in the United States in 2019, for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript.
  • The Morpholino antisense oligonucleotide viltolarsen (Viltepso) was approved for medical use in the United States in August 2020, for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
  • Casimersen (Amondys 45) was approved for medical use in the United States in February 2021, and it is the first FDA-approved targeted treatment for people who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
Clinical Rounds by ClinicHours

FDA approves new drug for Hemophilia A

The US FDA has approved efanesoctocog alfa (Altuviiio), a first-in-class, high-sustained factor VIII replacement therapy for adults and children with hemophilia A. The product is used once a week and is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as to control bleeding during surgery (perioperative management).

Clinical Inshorts by ClinicHours

Cannonball metastasis case

History: A 24-year-old male presented to the hospital with a cough productive of reddish sputum and shortness of breath of 6 days duration. The exam showed a left testicular mass. What’s the finding in the chest x-ray?

Answer: Cannonball metastases refer to multiple large, well-circumscribed, round pulmonary metastases. The primary tumors for these lesions can be remembered with the help of this mnemonic:

CRESP
Mnemonic
C: choriocarcinoma
R: renal cell carcinoma
E: endometrial carcinoma
S: synovial sarcoma
P: prostate carcinoma

Clinical Rounds by ClinicHours

FDA approves sacituzumab govitecan for HR+ metastatic breast CA

The US FDA approved a new indication for sacituzumab govitecan for patients with unresectable, locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer after endocrine-based therapy and at least two additional systemic therapies for metastatic disease.

Adverse events: decreased leukocyte count, decreased neutrophil count, decreased hemoglobin, decreased lymphocyte count, diarrhea, fatigue, nausea, alopecia, glucose elevation, constipation, and decreased albumin. Labeling for the agent carries a black box warning of severe or life-threatening neutropenia and severe diarrhea.

Dose: 10 mg/kg IV on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity.

Sacituzumab govitecan was previously approved for unresectable, locally advanced or metastatic triple-negative breast cancer after two or more prior systemic therapies and locally advanced or metastatic urothelial cancer after platinum-based chemotherapy and either a PD-1 or PD-L1 inhibitor.

Clinical Inshorts by ClinicHours

Cholesterol embolization syndrome case

History: A 60 yr old male had developed livedo reticularis on the left side of his face after he underwent stenting and balloon dilation of the left common carotid artery. Shivering, sweating, and confusion developed immediately after artery dilation, along with a left gaze preference, dysarthria, and hemiparesis on the right side of his body. Angiography showed a patent left internal carotid artery and an occluded distal left facial artery. No IC bleed on NCCT head. What’s the diagnosis?

Answer: The patient was transferred to the ICU, where MRI angiography of the brain revealed infarctions in the territory of the left middle cerebral artery with patent vasculature. An acute embolic stroke and cholesterol embolization syndrome of the face was diagnosed. In cholesterol embolization syndrome, atherosclerotic plaque contents from large-caliber arteries embolize to smaller arteries and lead to vascular occlusion, inflammation, and end-organ damage. Livedo reticularis is one of the most common skin manifestations of the syndrome. The patient received supportive care in the ICU. The livedo reticularis resolved 1 week after the event, but the neurologic deficits persisted at the time of his discharge from the hospital.

Clinical Rounds by ClinicHours

Auriculotemporal syndrome case

History: A healthy 1-year-old boy with the unremarkable medical history presented to a private clinic for a routine examination. Flushing & gustatory sweating was noted on the child’s left cheek. What’s the diagnosis?

Answer: Auriculotemporal nerve syndrome (Frey’s syndrome, Baillarger’s syndrome, Dupuy’s syndrome, or Frey-Baillarger syndrome) usually manifests as immediate unilateral or bilateral flushing, sweating in the distribution of the auriculotemporal nerve, or both in response to gustatory or tactile stimuli. In adults, this syndrome is a well-recognized sequela of parotid surgery, trauma, or infection. It occurs rarely in children, most often noted after the introduction of solid food. The flushing is often attributed erroneously to food allergy. It typically begins at 2–6 months of age when solid foods, mostly fruit, are introduced. Occurring within a few seconds of eating, it has a peculiar distribution in a triangular area that extends from the tragus of the ear to the midpoint of the cheek. It is not associated with sweating and persists for 20–60 min. The flushing continues to occur for up to 5 years. In adults, gustatory sweating is the predominant feature of auriculotemporal nerve syndrome; flushing happens less often. One-half of pediatric patients with this symptom were delivered with forceps assistance, which possibly causes trauma to the nerve. The likely mechanism is a misdirection of parasympathetic fibers along sympathetic pathways during the nerve regeneration that follows trauma. This may account for erythema when eating. The emergence of symptoms several months after the proposed trauma (usually 3–6 months) is probably related to the time required for nerve regeneration, and it is possible that vigorous chewing causes intense stimulation of the parotid gland.

Clinical Rounds by ClinicHours
error: